{"Symbol": "FOMX", "AssetType": "Common Stock", "Name": "Menlo Therapeutics Inc", "Description": "Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company's product pipeline includes FCD105 and FMX109 for the treatment of moderate-to-severe acne vulgaris; and FMX110 for the treatment of papulopustular rosacea. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; LEO Pharma A/S; Mylan N.V.; and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Other", "Industry": "Other", "Address": "2 Holzman Street, Weizmann Science Park\n7670402,Rehovot,ISR\n", "FullTimeEmployees": "80", "FiscalYearEnd": "December", "LatestQuarter": "0000-00-00", "MarketCapitalization": "183148864", "EBITDA": "-65312000", "PERatio": "None", "PEGRatio": "0", "BookValue": "0.876", "DividendPerShare": "None", "DividendYield": "0", "EPS": "-1.239", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "0", "ReturnOnEquityTTM": "0", "RevenueTTM": "0", "GrossProfitTTM": "3595000", "DilutedEPSTTM": "0", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "14.25", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "139.5828", "PriceToBookRatio": "3.4215", "EVToRevenue": "277.8461", "EVToEBITDA": "0", "Beta": "None", "52WeekHigh": "None", "52WeekLow": "None", "50DayMovingAverage": "2.99", "200DayMovingAverage": "3.6542", "SharesOutstanding": "57000000", "SharesFloat": "0", "SharesShort": "3328030", "SharesShortPriorMonth": "2669606", "ShortRatio": "0", "ShortPercentOutstanding": "0", "ShortPercentFloat": "0", "PercentInsiders": "0", "PercentInstitutions": "0", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "None", "LastSplitDate": "None"}